Co-Authors
This is a "connection" page, showing publications co-authored by TAO SHEN and VIVEK SUBBIAH.
Connection Strength
0.555
-
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer. NPJ Precis Oncol. 2024 Mar 04; 8(1):62.
Score: 0.235
-
The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib. NPJ Precis Oncol. 2021 Jun 07; 5(1):48.
Score: 0.195
-
Selpercatinib mitigates cancer cachexia independent of anti-tumor activity in the HT1080 tumor model. Cancer Lett. 2025 Jan 06; 611:217444.
Score: 0.062
-
Targeting Oncogenic RET Kinase by Simultaneously Inhibiting Kinase Activity and Degrading the Protein. J Med Chem. 2025 Jan 09; 68(1):81-94.
Score: 0.062